Indaptus Therapeutics
INDP
33 hedge funds and large institutions have $4.08M invested in Indaptus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 22 closing their positions.
58% more call options, than puts
Call options by funds: $76K | Put options by funds: $48K
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
30% less funds holding
Funds holding: 47 → 33 (-14)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
92% less capital invested
Capital invested by funds: $49.4M → $4.08M (-$45.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFCM
Taylor Frigon Capital Management
Scottsdale,
Arizona
|
+$551K |
| 2 |
VF
Virtu Financial
New York
|
+$176K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$113K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$86.3K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$62.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.81M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$3.56M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.54M |
| 4 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$3.17M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.69M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPC
51
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$80K | -8 | Closed |
|
52
Goldman Sachs
New York
| – | -$62K | -6 | Closed |
|
|
LI
53
Leap Investments
Chicago,
Illinois
| – | -$60K | -6 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$14.9K | -5 | Closed |
|
|
AS
55
Altshuler Shaham
Tel Aviv,
Israel
| – | -$27K | -3 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$26K | -3 | Closed |
|
57
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$10K | -1 | Closed |
|
|
EDRH
58
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$3K | – | – |
|
INDP Hedge Fund Activity: Q3 2019 in Review
33 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2019, worth a combined $4.08M — down 92% from $49.4M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of INDP and 11 opened new positions — a net loss of 11 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Taylor Frigon Capital Management, opening a new position worth an estimated $551K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $3.81M sold.
- 33 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2019, down from 47 in Q2 2019.
- Funds reported $4.08M of Indaptus Therapeutics stock for Q3 2019, down 92% quarter-over-quarter.
- 11 funds opened new Indaptus Therapeutics positions in Q3 2019 and 22 closed out, a net change of -11 holders.
- The largest Indaptus Therapeutics buyer in Q3 2019 was Taylor Frigon Capital Management, an estimated $551K added.
- The largest Indaptus Therapeutics seller in Q3 2019 was Sectoral Asset Management, an estimated $3.81M sold.
Based on aggregated 13F filings for Q3 2019.